Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Claudia Bertan
Observed name:
C. Bertan
Institution:
Institute of Cancer Research
Observed institution:
Institute of Cancer Research
ORCID:
0009-0009-2688-9067
Observed ORCID:
0009-0009-2688-9067
OpenAlex ID:
A5070892441
NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
·
Clinical Cancer Research
·
12
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer
2025
·
Juan M. Jiménez-Vacas
, Daniel Westaby
, et al.
·
Nature Communications
·
10
PDF
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
2026
·
Khobe Chandran
, Christina Guo
, et al.
·
Investigational New Drugs
·
2
PDF
An Open-label, Phase 1 Dose-finding Study of Single-agent IMU-935, a Novel RORγ/RORγt Inverse Agonist, in Patients with Progressive Metastatic Castration-resistant Prostate Cancer
2026
·
Rafael Grochot
, Christina Guo
, et al.
·
European Urology Oncology
·
2
Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers
2026
·
Alec Paschalis
, Ines Figueiredo
, et al.
·
Journal of Clinical Investigation
·
1
PDF
IAP antagonist tolinapant (ASTX660) in combination with pembrolizumab in advanced solid tumors: a phase I trial
2026
·
Crescens Tiu
, Wing Yau
, et al.
·
Nature Communications
PDF
Corrigendum to “B7-H3 as a Therapeutic Target in Advanced Prostate Cancer” [European Urology 83 (2023) 224–238
2026
·
Christina Guo
, Ines Figueiredo
, et al.
·
European Urology
Abstract 2585: Plasma cell-free DNA nucleosome footprints in metastatic castration-resistant prostate cancer (mCRPC)
2026
·
Denisa Bogdan
, Jan Rekowski
, et al.
·
Cancer Research
Abstract B032: Induction of the unfolded protein response unveils a vulnerability of advanced prostate cancer cells to BH3 mimetics
2026
·
Juan M. Jiménez-Vacas
, Jonathan Welti
, et al.
·
Cancer Research
Development of a circulating tumour DNA Assay in Patients with Malignant Pleural Mesothelioma
2026
·
Wei Yuan
, Kira-Lee Koster
, et al.
·
SSRN Electronic Journal
Figure 5 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S6 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Figure 1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Figure 3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S1 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S3 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Figure 4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S4 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Data from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S9 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S7 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Figure 2 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Figure S10 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Supplementary Tables S1-S13 from NXP800 Activates the Unfolded Protein Response, Altering AR and E2F Function to Impact Castration-Resistant Prostate Cancer Growth
2025
·
Jonathan Welti
, Denisa Bogdan
, et al.
Show more works
View as search
Works count:
29
Citation count:
27
H-index:
2
I10-index:
2
Year
Topic
Type